Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Mantle-Cell 7Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 3Waldenstrom Macroglobulinemia 2Recurrence 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Burkitt Lymphoma 1

Interventions

Biopsy 9Specimen Handling 8Magnetic Resonance Spectroscopy 6duvelisib 5Cyclophosphamide 5ruxolitinib 4Vincristine 410-propargyl-10-deazaaminopterin 4pembrolizumab 3X-Rays 3Prednisone 3Etoposide 3Doxorubicin 3tazemetostat 2sodium-iodide symporter 2cemiplimab 2belinostat 2Photons 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immunoglobulin G 2Disulfides 2Cytarabine 2Bortezomib 2Azacitidine 2venetoclax 1talimogene laherparepvec 1romidepsin 1prednylidene 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × Bendamustine Hydrochloride × 90 days × Clear all
NCT07225985 2026-05-11

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡